

Curriculum Vitae, ALLEGAERT KAREL



Personalia

Name : ALLEGAERT Karel Marcel
E-mail : karel.allegaert@uzleuven.be;
k.allegaert@erasmusmc.nl;

Work places: Department of development and regeneration, KU Leuven
Herestraat 49, 3000 Leuven, Belgium
Tel 32+16/343211 (secre)

Neonatal Intensive Care
Sophia's Children's Hospital, Erasmus MC
Wytemaweg, Rotterdam, the Netherlands
Internal postal address: SK5254

Summary

Prof dr Karel Allegaert, MD, PhD is pediatrician-neonatologist and clinical pharmacologist. He is associate Professor at KU Leuven (20%) and Consultant at Sophia children's hospital MC Rotterdam, NICU/PICU (80%).

He is former president of the European Society for Developmental Pharmacology and is former Board Member of the European Society for Pediatric Research (section clinical pharmacology). He is member of the Vlaamse Vereniging Kindergeneeskunde, Belgische Vereniging Kindergeneeskunde, Belgische Vereniging Neonatologie and the Nederlandse Vereniging Klinische Farmacologie en Biofarmacie. Related to the last mentioned society, he has recently been certified as trainer clinical pharmacology (formal training in clinical pharmacology as this (sub)discipline is a legal entity in the Netherlands). He's board member of clinical pharmacology working group of the International Neonatal Consortium initiative, an EMA/FDA supported initiative through the Critical Path Institute to improve neonatal drug development.

He was (co)promotor of 12 PhD projects, and was involved as member of the PhD jury of more than 50 in different universities and countries. His scientific outcome is reflected in more than

380 PubMed cited papers and 30 textbook chapters, with specific interests in the fields of perinatal clinical pharmacology and neonatal intensive care, including perinatal pain treatment (Web of Science H index 40).

In his clinical research activities, he has focussed mainly on perinatal and developmental pharmacology, with specific interest in perinatal and neonatal clinical pharmacology and the relevant co-variables (maturational, non-maturational, pharmacogenetics, disease-related, pregnancy related) of pharmacokinetics, and the subsequent use of in vivo datasets to develop prediction models. More recently, his research line has further expanded to in vitro models (placenta, renal tubular cells), in vivo model (bronchopulmonary dysplasia rabbit model) and to long term pharmacovigilance in former preterm neonates.

Such an approach necessitates (inter)national collaboration, as reflected in publications with >500 co-authors from >50 different international research groups. The scientific output can be retrieved in commonly used and accessible websites like ResearchGate (https://www.researchgate.net/profile/Karel_Allegaert), or ORCID (<https://orcid.org/0000-0001-9921-5105>). These collaborations also cover clinical research groups located in Switzerland, most prominent with Basel University, but more recently also with the University of Zurich and the University of Lausanne.

He is editorial board member of international journals, including Archives of Diseases in Childhood, Neonatology, Hypertension, Clinical Pharmacokinetics, European Journal of Clinical Pharmacology, Frontiers in Pediatrics, BMJ Pediatrics Open, and European Journal of Pediatrics. Similar, he's very actively involved in reviewing activities for a variety of medical journals, as can be retrieved at Publons website: <https://publons.com/researcher/1357520/karel-allegaert>.

Finally, he has been involved as Principal investigator in about 25 academia and 10 sponsor initiated studies and has experience with consultancy and served as member of DSMB for both sponsored as well as academia initiated studies. Funding to perform this research has been driven by charity and university related funding (SSWO funding Erasmus MC, KOOR funding Leuven), as well as national funding agencies (IWT, FWO Vlaanderen, ZONNW) or international funding authorities (FP7, IMI).

These activities have resulted in relevant awards like the Galenus clinical researcher award (Belgium, 2009) for neonatal clinical pharmacology research, the Belgian Pain Society Award (2005), the Govaerts price for clinical toxicology (2006) and the Heymans price for clinical pharmacology (2008). He has been appointed as ordinary member of the Royal Academy of Medicine, Belgium (2015).

Relevant links

<https://publons.com/researcher/1357520/karel-allegaert>.

<https://orcid.org/0000-0001-9921-5105>

https://www.researchgate.net/profile/Karel_Allegaert

<https://www.ncbi.nlm.nih.gov/pubmed/?term=allegaert+k>